

# Late Effects of Parasellar Lesion Treatment: Hypogonadism and Infertility

Emilia Sbardella<sup>a</sup> Marianna Minnetti<sup>a</sup> Riccardo Pofi<sup>a</sup> Alessia Cozzolino<sup>a</sup>  
Ermanno Greco<sup>b</sup> Daniele Gianfrilli<sup>a</sup> Andrea M. Isidori<sup>a</sup>

<sup>a</sup>Department of Experimental Medicine, Sapienza University of Rome, Policlinico Umberto I Hospital, Rome, Italy;

<sup>b</sup>Center for Reproductive Medicine, European Hospital, Rome, Italy

## Keywords

Parasellar lesions · Cancer survivors · Hypogonadism · Infertility · Pregnancy

## Abstract

Central hypogonadism, also defined as hypogonadotropic hypogonadism, is a recognized complication of hypothalamic-pituitary-gonadal axis damage following treatment of sellar and parasellar masses. In addition to radiotherapy and surgery, CTLA4-blocking antibodies and alkylating agents such as temozolomide can also lead to hypogonadism, through different mechanisms. Central hypogonadism in boys and girls may lead to pubertal delay or arrest, impairing full development of the genitalia and secondary sexual characteristics. Alternatively, cranial irradiation or ectopic hormone production may instead cause early puberty, affecting hypothalamic control of the gonadostat. Given the reproductive risks, discussion of fertility preservation options and referral to reproductive specialists before treatment is essential. Steroid hormone replacement can interfere with other replacement therapies and may require specific dose adjustments. Adequate gonadotropin stimulation therapy may enable patients to restore gametogenesis and conceive spontaneously. When assisted reproductive technology is need-

ed, protocols must be tailored to account for possible long-term gonadotropin insufficiency prior to stimulation. The aim of this review was to provide an overview of the risk factors for hypogonadism and infertility in patients treated for parasellar lesions and to give a summary of the current recommendations for management and follow-up of these dysfunctions in such patients. We have also briefly summarized evidence on the physiological role of pituitary hormones during pregnancy, focusing on the management of pituitary deficiencies.

© 2020 S. Karger AG, Basel

## Introduction

The parasellar region is a highly complex and fragile area without any strong anatomic boundaries. It comprises structures and spaces surrounding the sella turcica, namely the suprasellar cistern, the cavernous sinus, the hypothalamus and the third ventricle [1, 2]. In the long term, patients with a parasellar lesion are likely to develop endocrine disorders, resulting from either the tumorous

This work was presented in part during the 6th ENEA Workshop on Parasellar Lesions in Athens, Greece.

or infiltrative process itself or its treatments, which can have both local and distal side effects. Masses occupying the parasellar region are normally due to a pituitary adenoma extending from the sella. Less frequently, they may arise from a primary parasellar tumour or a non-tumorous cystic lesion [1]. The most common malignant lesions occupying the parasellar region are gliomas, followed by germ cell tumours, primary lymphomas and metastases. Other potentially malignant tumours include craniopharyngiomas, chordomas, chondrosarcomas, haemangiopericytomas and Langerhans cell histiocytosis, while benign tumours include meningiomas, epidermoid cysts, dermoid cysts and Rathke cysts [2].

The diagnostic approach to a suspected suprasellar/parasellar lesion should start with radiological imaging. Computed tomography scans are generally considered to offer the most information, as they enable an accurate assessment of bony details and calcifications. However, magnetic resonance imaging is the imaging technique of choice, as it produces multiplanar high-contrast images, while more recent advanced magnetic resonance imaging techniques such as diffusion-weighted imaging and perfusion-weighted imaging [3–5] can better define the morphological characteristics of the lesion.  $^{18}\text{F}$ -fluoro-deoxyglucose and  $^{68}\text{Ga}$ -positron emission tomography can be used for functional imaging, but only in specific tumour settings [6, 7].

The second diagnostic step is a complete pre-treatment evaluation of hormone deficiencies, to help establish the prognosis and initiate a suitable therapy. A complete description of the tests used to investigate the hypothalamic-pituitary axis in men and women was previously provided [8–11]; a brief summary is reported in Table 1.

### **Parasellar Lesions: The Effects of Treatment**

The remarkable improvement in the survival of children and adults diagnosed with cancer and the high incidence of chronic disorders in adult survivors of childhood cancer highlight the importance of recognizing factors predictive of and responsible for future morbidities [12]. Changes in hypothalamic, pituitary and peripheral gland function are frequently described in childhood cancer survivors [13–15]. Recognition of such changes is particularly important given their association with impaired growth, pubertal development and reproductive function, decreased bone mineral density, a higher prevalence of infectious diseases, and

poor quality of life [16–18]. The endocrine risks associated with the various treatments for parasellar lesions are described in Table 2.

For slow-growing lesions, surgery to remove as much of the mass as possible is generally the first treatment choice. Radiotherapy is generally used to prevent recurrences. Primary or adjuvant medical therapy and radiotherapy may be an option for highly recurrent or particularly aggressive lesions, as well as for lesions at risk of becoming malignant. In the management of these patients, it is essential to minimize the undesirable effects of the treatments, promptly diagnose any hormone deficiencies [19, 20] and initiate hormone replacement therapy (HRT), where indicated [21–25]. Central hypogonadism, also known as hypogonadotropic hypogonadism (HH), may occur after surgery, cranial irradiation of parasellar tumours such as craniopharyngioma or germinoma, or hypothalamic-pituitary diseases, such as in patients with glioma. Overall, the incidence of HH amongst childhood cancer survivors has been reported as 6.3% [26].

The risk of infertility in adults depends on complex interactions between the characteristics of the tumour (histology, proximity to the hypothalamus), the individual patient (age, sex, genetic predisposition, pre-existing polycystic ovary syndrome in females) and the treatment (radiation, high-dose chemotherapy, especially with alkylating agents, immunotherapies, high-dose glucocorticoids) [27–29].

#### *Radiotherapy and Its Effects on the Hypothalamic-Pituitary-Gonadal Axis*

In recent decades, the survival rates following a childhood brain tumour have increased to 75%. This has raised interest in the undesirable effects of its treatments [30]. Radiation-induced anterior pituitary hormone deficiency is the most common irreversible long-term complication of cancer treatment. It is now estimated that up to 50% of treated childhood cancer survivors will eventually develop an endocrinopathy. Strict follow-up is required to minimize the detrimental effects of the treatment on growth, bone density, pubertal development, fertility and quality of life [13]. The neurotoxicity induced by radiotherapy depends on the total dose, the fraction size and the duration of the radiation programme [31–34].

Significant improvements in imaging techniques and radiotherapy technology have enabled more precise, accurate and focal irradiation with fewer side effects. Radiation techniques for patients with sellar/parasellar lesions have evolved from 3D conformal radiotherapy to

**Table 1.** Summary of tests used to investigate the HPG axis in men and women to rule out primary and secondary hypogonadism

| Test  | Females   |   |   |  |   |   |   |   |
|---|---|---|---|--|---|---|---|---|
|   | Males   | primary hypogonadism (gonadal failure following chemotherapy or radiotherapy)   | secondary hypogonadism (acquired hypothalamic defect)   | secondary hypogonadism (acquired hypopituitarism/deficiency)                                 | secondary hypogonadism (gonadal failure following chemotherapy or radiotherapy)                         | primary hypogonadism (gonadal failure following chemotherapy or radiotherapy)                           | secondary hypogonadism (acquired hypothalamic defect)   | secondary hypogonadism (acquired hypopituitarism/deficiency)  |
| Baseline examinations to evaluate HPG axis function   | LH, FSH, total T, SHBG, inhibin B, albumin      | LH, FSH, total T, SHBG, inhibin B, albumin  | LH, FSH, total T, SHBG, inhibin B, albumin  | LH, FSH, oestradiol, PRL, AMH (in pre-menopausal women only, as a marker of ovarian reserve) | LH, FSH, oestradiol, PRL, inhibin B, AMH (in pre-menopausal women only, as a marker of ovarian reserve) | LH, FSH, oestradiol, PRL, inhibin B, AMH (in pre-menopausal women only, as a marker of ovarian reserve) | LH, FSH, oestradiol, PRL, inhibin B, AMH (in pre-menopausal women only, as a marker of ovarian reserve)   | LH, FSH, oestradiol, PRL, inhibin B, AMH (in pre-menopausal women only, as a marker of ovarian reserve)   |
| Expected baseline examination results   | Usually high LH, high FSH, low T, low inhibin B | Usually normal/low LH, normal/low FSH, low T, low inhibin B   | Usually normal/low LH, normal/low FSH, low T, low inhibin B   | Usually normal/low LH, low FSH, low oestradiol, normal PRL, low AMH                          | Usually normal/low LH, low FSH, low oestradiol, normal PRL, low AMH                                     | Usually normal/low LH, low FSH, low oestradiol, normal PRL, low AMH                                     | Usually normal/low LH, low FSH, low oestradiol, normal PRL, low inhibin B, normal/low AMH   | Usually normal/low LH, low FSH, low oestradiol, normal PRL, low inhibin B, normal/low AMH   |
| Dynamic tests to evaluate HPG axis function and expected results  |   |   |   |  |   |   |   |   |
| Expected GnRH test results  | Not indicated                                   | Potentially excessive LH response if recent, or a reduced response if longstanding; if longstanding, priming with repeated doses of GnRH may induce a normal response | Reduced response; a 36-h priming with GnRH is suggested prior to the classic GnRH test; after GnRH priming, the LH increment is 5 times lower than normal; ratio of the maximum delta of FSH/LH >0.55 | Not indicated  | Not indicated   | Not indicated   | Usually normal or reduced response of LH and FSH pulses; most patients with low LH and FSH baseline values show a minimal response to GnRH; priming with GnRH is suggested prior to the classic GnRH test in cases of reduced LH and FSH response | Usually normal or reduced response of LH and FSH pulses; most patients with low LH and FSH baseline values show a minimal response to GnRH; priming with GnRH is suggested prior to the classic GnRH test in cases of reduced LH and FSH response |
| Expected HCG test results   | Not indicated                                   | With recent hypothalamic dysfunction and in post-pubertal boys, T may increase normally; T does not increase to normal <sup>1</sup> range in pre-pubertal boys        | Normal T response; 2- to 3-fold increase in T if disease presented in adulthood; T does not rise normally in prepubertal hypogonadism   | Not indicated  | Not indicated   | Not indicated   | Not indicated   | Not indicated   |
| Expected domiphene test results   | Not indicated                                   | Lack of LH and FSH response; second choice among dynamic HPG axis tests   | Lack of LH and FSH response; second choice among dynamic HPG axis tests   | Not indicated  | Not indicated   | Not indicated   | Reduced or no LH, FSH, and oestradiol response; occasionally used to evaluate dynamic HPG axis function, to differentiate between normal subjects and patients with HH  | Reduced or no LH, FSH, and oestradiol response; occasionally used to evaluate dynamic HPG axis function, to differentiate between normal subjects and patients with HH  |
| Expected oestrogen/progestogen challenge test results (in case of secondary amenorrhoea and a negative pregnancy test, if no withdrawal bleeding) | Not indicated                                   | Not indicated   | Not indicated   | Usually withdrawal bleeding  | Usually withdrawal bleeding   | Usually withdrawal bleeding   | Usually withdrawal bleeding   | Usually withdrawal bleeding   |

HPG, hypothalamic-pituitary-gonadal; T, testosterone; LH, luteinizing hormone; FSH, follicle-stimulating hormone; SHBG, sex hormone-binding globulin; PRL, prolactin; AMH, anti-Müllerian hormone; GnRH, gonadotropin-releasing hormone; HH, hypogonadotropic hypogonadism. <sup>1</sup> Normal level for age-adjusted reference range.

**Table 2.** Endocrine complications of the common treatments for parasellar lesions

| Treatment                                    | Associated endocrine complications  |
|--|---|
| Cranial irradiation                          | Low dose (18–24 Gy):<br>– Precocious puberty in girls<br>– Growth hormone deficiency<br>High dose ( $\geq 24$ Gy):<br>– Precocious puberty in both sexes<br>– Central hypothyroidism<br>– Central hypoadrenalism<br>– Delayed puberty – hypogonadism ( $\geq 30$ Gy)<br>– Hyperprolactinaemia ( $\geq 50$ Gy)<br>– Hypothalamic obesity ( $\geq 50$ Gy) |
| Surgery in the hypothalamic-pituitary region | Hypopituitarism<br>Hyperprolactinaemia<br>Precocious puberty<br>Absent/delayed puberty due to hypogonadism<br>Hypothalamic obesity<br>Diabetes insipidus  |
| Alkylating agents                            | Primary hypogonadism<br>Delayed puberty (especially in girls)   |
| Anti-CTLA-4-antibody therapy                 | Hypopituitarism due to hypophysitis<br>Thyroid dysfunction<br>Primary adrenal insufficiency<br>Hyperglycaemia   |
| Glucocorticoids                              | Hypogonadism<br>Delayed puberty<br>Growth failure   |

stereotactic techniques (stereotactic radiosurgery or fractionated stereotactic radiotherapy). The aim is to deliver high radiation doses with a steeper dose gradient between the tumour and the surrounding neurovascular structures, thus reducing the long-term adverse effects [35, 36].

The secretion of gonadotropin-releasing hormone (GnRH), follicle-stimulating hormone (FSH) and luteinizing hormone (LH) follows a pulsatile rhythm, which is responsible for the efficient development of the reproductive system [37]. Radiation-induced gonadotropin deficiency shows a wide range of clinical expression, from subclinical impairment to severe forms. Generally, the cumulative incidence of gonadotropin deficiency during long-term follow-up is about 20–50%, regardless of whether radiotherapy was received in childhood or adulthood [38]. Disturbances of the pulsatile rhythm of FSH/LH production can affect puberty, fertility and libido in both males and females [39].

### *Chemotherapy, Immunological Treatment and Their Effects on the Hypothalamic-Pituitary-Gonadal Axis*


In men, even low doses of alkylating agents such as temozolomide can exert cytotoxic effects on Sertoli, Leydig and germ cells. In women, they are responsible for a higher age-adjusted odds ratio of ovarian failure [40, 41].

The increasing use of immunological treatments has resulted in a growing number of reports of endocrine side effects, including hypophysitis [42]. Specific pituitary side effects have been described with CTLA4-blocking antibodies such as ipilimumab and tremelimumab. These can cause autoimmune diseases in up to 70% of patients [43, 44], of whom about 17% may present autoimmune hypophysitis during treatment. Patients developing hypophysitis may also develop LH and FSH deficiencies as well as adrenocorticotropin hormone, thyroid-stimulating hormone (TSH) and in some cases growth hormone (GH) deficiency (GHD), diabetes insipidus (DI) or syndrome of inappropriate antidiuretic hormone secretion [45–47]. The onset of hypophysitis and hence of hypopituitarism should be promptly diagnosed and treated [48]. HH has been described in 83–87% of male patients with hypophysitis treated with anti-CTLA4 antibodies [49]. Moreover, we should consider the effects of long-term treatment with glucocorticoids, used in cancer patients for multiple reasons such as for the anti-inflammatory action in the management of peritumoural brain oedema, to prevent nausea, vomiting, and hypersensitivity reactions to treatment with chemotherapy or radiation. This treatment can lead to suppressed gonadotropin secretion, and therefore to hypogonadism and delayed puberty [41, 50].

### **Long-Term Effects of Parasellar Lesion Treatments on Male Gonad Function**

#### *Male Central Hypogonadism*

Boys presenting hypogonadism secondary to neurosurgery or radiotherapy at the time of normal puberty must undergo treatment to induce puberty. This is particularly important to achieve normal testicular volumes, penile length and secondary sexual characteristics [51]. Sex steroid replacement in males may be started from around 13 years, depending on the family history of pubertal development, psychosocial development, height and skeletal maturation [26]. The therapy usually involves testosterone esters given by intramuscular injection, but recent studies also call for the use of other tes-



**Fig. 1.** Treatment of infertility in men with hypogonadotropic hypogonadism. This figure was created using Servier Medical Art templates, which are licensed under a Creative Commons Attribution 3.0 Unported License; <https://smart.servier.com>. hCG, human chorionic gonadotropin; hMG, human menopausal gonadotropin; FSH, follicle-stimulating hormone.

tosterone formulations such as transdermal gels that can be started when about 50% of the adult dose with i.m. testosterone has been achieved [52, 53].

Depending on the formulation used (testosterone enanthate, cypionate and propionate), the starting dose is normally 50–100 mg by i.m. injection every 4 weeks for 3–6 months, which is usually enough to achieve early virilization and growth without undesirable effects on epiphyseal maturation and bone age [52, 54]. After these first 6 months, the testicular volume should be rechecked, and if it is still <8 mL, a new treatment cycle and a gradually increased dose over 2–3 years is recommended to achieve normal growth and pubertal development, until the normal dose for adults is reached [52].

Puberty in adolescent males can also be induced with human chorionic gonadotropin (hCG), either as monotherapy or in combination with recombinant FSH. This might result in better testicular growth and penile length [55, 56], and is also the preferred approach to safeguard reproductive capacity, because early induction of spermatogenesis may increase sperm production and reduce the time required for the future appearance of sperm [55]. There is now an increasing consensus that puberty in HH should be initiated with gonadotropins, with testosterone priming only if delayed puberty is suspected. This approach is based on better outcomes in terms of testicular volume and spermatogenesis. Some recent evidence suggests that FSH should be given prior to hCG or testosterone to increase the sperm population, thus improving the response to subsequent stimulation [52, 57]. It is essential to consider the need for a prostate check-up before starting testosterone therapy [58–60].

### Male Infertility

In adult men with secondary hypogonadism, testosterone treatment should be started soon after glucocorticoid and levothyroxine replacement therapy if multiple pituitary deficiencies are present [61, 62], but stopped before trying to conceive [63]. At this point, sperm production can be stimulated to restore fertility. Gonadotropin treatment results in the appearance of sperm in the ejaculate in up to 90% of subjects [64]. The first-line treatment is always hCG, for many reasons: it has the same biological activity as human LH, but with a longer half-life; it stimulates the Leydig cells to secrete testosterone; and it also increases the intratesticular testosterone concentration, which is essential for spermatogenesis [65, 66]. hCG is usually started intramuscularly at an initial dose of 3,000–5,000 units, divided into 2–3 doses a week. Blood testosterone concentrations should be checked every 1–2 months, and if not in the normal range, the hCG dose should be increased accordingly. The total sperm number is measured every 1–3 months once a normal serum testosterone concentration has been achieved, but it is not used as a parameter for tailoring hCG doses [67]. If the total sperm number has not reached half-normal values and/or pregnancy has not been achieved within 6 months of hCG treatment, recombinant human FSH or human menopausal gonadotropin (which contains both FSH and LH) can be added. The initial dose is 75–150 units 3 times a week, and again, the total sperm number should be measured every 1–3 months.

The treatment of infertility in men with HH is summarized in Figure 1. The time to achieve a near-normal



total sperm number in the ejaculate differs from patient to patient, but it can take up to 18–24 months [68].

Gonadotropin therapy is effective in inducing spermatogenesis in HH from both hypothalamic and pituitary causes. A better response has been obtained in patients with postpubertal onset of HH, in subjects with lower gonadotropin levels at enrolment and in patients with a pure secondary hypogonadism origin (low gonadotropins) [69]. The addition of FSH to hCG was associated with a better outcome, with similar results achieved for different FSH preparations (urinary derived, highly purified or recombinant) [69]. Other baseline predictors of successful spermatogenesis induction are a testicular volume >4 mL, a serum inhibin B level >60 pg/mL and the absence of previous cryptorchidism [70]. It should also be borne in mind that the outcome of gonadotropin therapy does not seem to be affected by previous testosterone replacement therapy.

The current 69–81% success rate for achieving spermatogenesis confirms the efficacy of gonadotropin replacement therapy in HH patients [69, 71]. Various studies report a mean sperm concentration of about 6 million per millilitre after gonadotropin treatment, which is usually considered sufficient to achieve fertility in HH patients [72, 73].

Although spontaneous conception might not be possible, pregnancy can often be achieved with the help of assisted reproductive technology (ART) or intrauterine insemination [74]. It has been reported that gonadotropin treatment improves the results of testicular sperm extraction/intracytoplasmic sperm injection, which can be performed in HH patients showing persistent azoospermia after hormone therapy [75, 76].

Cryopreservation of sperm should generally be offered before any chemotherapy, and above all once a normal sperm count has been achieved. Virilization can be maintained in men not wishing to have more children by continuing hCG alone or better returning to testosterone therapy.

### **Long-Term Effects of Parasellar Lesion Treatments on Female Gonad Function**

#### *Early Puberty*

Treatment of intracranial tumours in prepubescent children can lead to abnormalities of puberty. Cranial irradiation can cause early puberty, mainly due to hypothalamic dysfunction [39]. Low doses (18–24 Gy) are associated with precocious puberty only in girls, while higher

doses affect both sexes [77]. In girls with precocious puberty, depot GnRH analogues are the standard of care [41].

#### *Female Central Hypogonadism*

The risk of hypogonadism is related to age, pubertal development at the time of diagnosis, tumour site, treatment type and dosage [41]. The timing and dosage in patients with HH are the same as for girls with Turner syndrome or other causes of premature ovarian insufficiency [26].

In girls with a diagnosis of HH secondary to parasellar lesion treatment, oestrogen replacement therapy should be started at the age of 12–13 years [78], beginning at a low dose (one-eighth to one-quarter of the adult dose) and increasing it gradually to full adult replacement levels. A possible dose regimen is a patch containing 25 µg of 17β-oestradiol/24 h cut into 4 equal-sized pieces, applying one to the skin before going to bed and removing it the following morning. After 4–6 months the dose can be increased to 2 pieces at night, with one piece being removed the following morning and the other remaining on the skin all day. This dosage is usually increased about every 4–6 months, to one patch of 25–100 µg positioned continuously and changed twice a week. Alternatively, 0.5 mg of oral 17β-oestradiol can be taken every day or every other day as an initial dosage, increasing gradually [79].

When “breakthrough” bleeding occurs or after 1 or 2 years, oestrogen treatment with cyclic progesterone should be initiated to avoid endometrial hypertrophy [52, 79]. Progesterone can be cycled using either medroxyprogesterone at 5–10 mg or micronized progesterone at 100–200 mg for 10–14 days [52, 79]. In cases of simultaneous GHD, it might be decided to start GH replacement therapy before oestrogen replacement to ensure an adequate pubertal growth rate; however, this choice should be made on a case-by-case basis [26].

If hypogonadism arises after puberty, HRT is necessary. HRT until or beyond the age of natural menopause may reduce the risk of cardiovascular disease and mortality [61] and alleviates the vasomotor symptoms of hypogonadism. Oestrogen replacement may involve sequential oestrogens plus progesterone for 10–14 days or combined hormonal contraceptive pills. Oestrogen replacement therapy in hypogonadal women also protects against bone fractures [80].

Many different oestrogen formulations are available, including oral and transdermal, topical gels and lotions, intravaginal creams and tablets, and vaginal rings. When compared with transdermal formulations, oral oestro-

gens have unfavourable effects on lipid metabolism, inflammation and coagulation factors [81, 82]. Oral oestrogens significantly increase thyroid-binding globulin and cortisol-binding globulin (CBG) production and may also reduce IGF-1 levels. An increase in levothyroxine, glucocorticoids and GH doses may therefore be required in patients with hypothyroidism, adrenal insufficiency and GHD, respectively [22, 61]. Furthermore, the increase in CBG in response to oral oestrogens may give falsely normal levels of serum cortisol in patients with secondary adrenal insufficiency. Ethinyl oestradiol exerts a stronger effect than natural oestradiol on hepatic metabolism [83]. Progestogen should be given in combination with oestrogen therapy to prevent endometrial hyperplasia in women with an intact uterus [84]. The combined oestrogen-progestin contraceptive pill is sometimes better accepted by younger women [25]. There is a lack of specific studies on patients with central hypogonadism comparing the effects of sequential replacement of oestrogens and progestins and combined oestrogen-progestin contraceptive pills. The published evidence in relation to HRT in patients with HH refers to women with primary hypogonadism.

It should be noted that poor libido in women with combined gonadotropins and adrenocorticotropin hormone deficiencies may be due to androgen deficiency [25]. At present, the evidence-based indication for testosterone therapy in women is hypoactive sexual desire disorder, diagnosed in postmenopausal women after a complete biopsychosocial assessment [85]. The Endocrine Society's guidelines recommend against the routine use of dehydroepiandrosterone and testosterone in women with hypopituitarism or adrenal insufficiency, due to limited data concerning its effectiveness and safety [61]. There is a lack of dedicated studies on androgen therapy in women with central hypogonadism associated with hypoadrenalism.

### *Female Infertility*

Women and girls with parasellar lesions are at risk of infertility because of the potential detrimental effects of surgery and radiotherapy on the hypothalamic-pituitary axis. Retrospective studies report pregnancy rates of between 47 and 76% amongst women with hypopituitarism [86–90]. In childhood, both hypopituitarism and isolated HH may lead to smaller uterine dimensions and ovarian volume compared with healthy controls [91]. When compared with women with isolated HH, patients with combined pituitary hormone deficiencies involving HH have fewer ovulatory cycles and worse pregnancy rates after

controlled ovarian stimulation [87, 88]. To achieve pregnancy, patients with HH need ovulation induction or ART [92, 93]. Given the improved prognosis of some parasellar lesions and improvements in ART, fertility preservation strategies such as embryo and oocyte cryopreservation should be performed before radiotherapy or chemotherapy [39]. Embryo cryopreservation is the most effective option, while oocyte cryopreservation is used for prepubertal girls and women without a partner or sperm donor or with ethical objections to embryo storage. Both techniques include controlled ovarian hyperstimulation and oocyte retrieval. Ovarian tissue cryopreservation has only been performed under experimental protocols [41].

Women with reduced pituitary gonadotropic function due to pituitary diseases cannot benefit from pulsatile GnRH treatment to induce ovulation, although, conversely, this can be successful in women with hypothalamic amenorrhoea [94]. Different controlled ovarian stimulation (COS) protocols have been proposed for women with HH, involving human menopausal gonadotropin alone or combined with urinary FSH, recombinant FSH or low-dose hCG. Other protocols involve recombinant FSH with LH. COS protocols for assisted reproduction in women with HH are described in Table 3. The reported pregnancy rates after COS amongst HH women vary wildly, from 19.4 to 100%, with a 3.6–41.7% risk of multiple pregnancies [88–90, 95–100]. Higher gonadotropin doses are generally used than in patients with other causes of infertility [101]. Antral follicle count, ovarian volume and anti-Müllerian hormone levels are not useful to predict treatment response in women with HH [102].

### **Other Endocrine Effects Affecting Fertility**

Hyperprolactinaemia can develop after surgery, after any disease disrupting pituitary stalk integrity and after hypothalamic irradiation with  $\geq 50$  Gy. It is associated with delayed puberty, menstrual irregularity, galactorrhoea, decreased libido, sexual dysfunction and infertility. Dopamine agonists can restore gonadal function [41].

It is well known that GH affects both male and female fertility [103]. GH acts on the testes both directly and indirectly via IGF-1, promoting sperm production, mostly through autocrine and paracrine functions [104]. In male patients with GHD, GH therapy seems not to affect testosterone levels [105]. In patients with HH, adjuvant GH therapy would seem to improve sperm motility in non-responders to gonadotropins, even though the data are not univocal [106, 107]. Isolated GHD in girls during

**Table 3.** Main controlled ovarian stimulation protocols for assisted reproduction in women with hypogonadotropic hypogonadism

| Characteristics    | Studies [Ref.], year type   | Patients, <i>n</i>  | Doses   | Ovulation rate, %  | Pregnancy rate, % | Multiple gestations, % |      |
|--------------------|---|---|---|--|-------------------|------------------------|------|
| hMG                | Fixed LH/FSH ratio (1:1)<br>Easy availability and low cost<br>Daily subcutaneous administration started between menstrual cycle days 3 and 7<br>Dose incrementation of approximately 33% based on ultrasound findings<br>Higher doses are needed for HH than for PCOS     | White et al. [89], 2018<br>Retrospective study            | 80 HH<br>(7 with pituitary deficiency following neurosurgery) | Starting dose of hMG: median 113 IU/day<br>2,500 IU of hCG administered at follicular maturation time to trigger ovulation   | 84                | 65                     | 5    |
|                    |   | Martin et al. [95], 1993<br>Retrospective study           | 30 HH<br>(11 had a history of pituitary tumours)              | Starting dose of hMG: 150 IU/day<br>3,000–5,000 IU of hCG at follicular maturation time to trigger ovulation   | 97                | 72                     | 14.8 |
|                    |   | Correa et al. [88], 2017<br>Prospective study             | 5 childhood-onset combined pituitary hormone deficiency       | Starting dose of hMG: 75 IU/day (IUI) to 150 IU/day (IVF)<br>250 µg of recombinant hCG administered at follicular maturation time to trigger ovulation   | /                 | 100                    | 20   |
|                    |   | Balen et al. [130], 1994<br>Retrospective study           | 77 HH   | Starting dose of hMG: 75 IU  | 75.2              | 83                     | 3.6  |
| hMG + uFSH         | Step-up protocol<br>uFSH has lower cost than rFSH   | Pandurangi et al. [96], 2015<br>Retrospective study       | 7 HH  | hMG 75–150 IU + uFSH 150–225 IU<br>Ovulation was induced by a single IM administration of uHCG 10,000 IU   | 70                | 68.6                   | 14.2 |
| hMG + rFSH         | Longer stimulation and duration and higher gonadotropin dose in HH patients than in patients with unexplained infertility or tubal factor infertility   | Kumbak and Kahraman [97], 2006<br>Retrospective study     | 27 HH   | hMG 300–600 IU/day + rFSH 150–450 IU<br>An injection of 10,000 IU of hCG was administered to trigger ovulation   | 72                | 59                     | 3.7  |
|                    |   | Ghaffari et al. [98], 2013<br>Retrospective study         | 81 HH   | Daily hMG (75 IU ± rFSH 75 IU)<br>Ovulation was triggered with 10,000 IU of hCG  | 93.8              | 19.4                   | 5.5  |
| hMG + low-dose hCG | hCG has a lower cost, longer half-life and higher affinity for receptors than rLH<br>HH patients require a longer duration and higher dose of hMG, even with the addition of low-dose hCG, than patients with tubal factor infertility                                    | Jiang and Kuang [99], 2018<br>Retrospective study         | 46 HH   | hMG 150 IU/day or 225 IU/day + hCG injections 50–300 IU/day<br>Ovulation was triggered by hCG 5,000 IU   | 64.2              | 59.5                   | 41.7 |
| rFSH + rLH         | Safe and effective in inducing follicular development in HH women with marked gonadotropin deficiency<br>FSH and LH dose ratio can be altered to 2:1<br>Higher cost than hMG  | Kaufmann et al. [131], 2007<br>Open-label, RCT            | 31 HH   | A fixed dose of lutropin alfa 75 IU and an individualized dose of follitropin alfa (initial dose 75–150 IU and up to 225 IU once daily SC)<br>10,000 IU of hCG administered at follicular maturation time to trigger ovulation | 92                | 59.3                   | 19.3 |
|                    |   | Carone et al. [132], 2012<br>Randomized, open-label study | 17 HH   | 150 IU r-hFSH and 75 IU r-hLH daily<br>Ovulation was induced by a single administration of 10,000 IU of hCG  | 70                | 55.6                   | 11.7 |
| Pulsatile GnRH     | Suitable only for women with an intact pituitary gland<br>Maintains normal pituitary-ovarian feedback<br>Need to attach a pump, which can cause discomfort<br>More expensive than hMG injections<br>Reduces the risk of multiple pregnancies and ovarian hyperstimulation | Martin et al. [95], 1993<br>Retrospective study           | 41 HH   | 75–250 ng/kg   | 93                | 96                     | 8.3  |

FSH, follicle-stimulating hormone; GnRH, gonadotropin-releasing hormone; hCG, human chorionic gonadotropin; HH, hypogonadotropic hypogonadism; hMG, human menopausal gonadotropin; IM, intramuscular; IUI, intrauterine insemination; IVF, in vitro fertilization; LH, luteinizing hormone; PCOS, polycystic ovary syndrome; rFSH, recombinant FSH; r-hFSH, human recombinant FSH; r-hLH, human recombinant LH; rLH, recombinant LH; SC, subcutaneous; uFSH, urinary FSH.

childhood is associated with a small uterus, suggesting that GH might have an independent effect in determining uterus size [91]. GH is involved in ovulation, oocyte quality and competence, increases in follicular growth, and modulation of progesterone and oestradiol release through both GH and IGF-1 receptor expression on ovarian cells [103, 108, 109]. Spontaneous conception can be achieved by women with GHD as long as the hypothalamic-pituitary-gonadal (HPG) axis is intact and ade-

quate HRT is given [110]. Although there are numerous articles discussing GH supplementation during ART for women with normal pituitary function [111], the only evidence of improved oocyte quality after GH administration in women with GHD comes from case reports [109].

TSH deficiency usually occurs after gonadotropin and GHD in patients with hypopituitarism. There is little information on how central hypothyroidism affects fertility, although thyroid hormones have an important role in



**Table 4.** Suggested management of hypopituitarism in pregnancy

| Disease  | Preconception  | 1st trimester  | 2nd trimester   | 3rd trimester  | Delivery   | Post-partum  |
|--|--|--|---|--|--|--|
| HPA axis   | Hydrocortisone 10–12 mg/m <sup>2</sup> /day (commonly 15–20 mg/day) in 2 or 3 divided oral doses<br>Cortisone acetate (once daily 25–37.5 mg/day), prednisone or prednisolone (3–5 mg/day) could potentially be used <sup>1</sup><br>Avoid dexamethasone, as it is not inactivated by 11 $\beta$ -HSD2 | Continue preconception doses<br>No need to increase GC replacement dose unless there is evidence of intercurrent illness<br>Consider parenteral GCs for intractable vomiting   | No need to increase GC replacement dose unless there is evidence of intercurrent illness                | Adjust according to clinical course<br>Usually no need to increase GC replacement dose, but some authors suggest a 20–40% increase | 100 mg hydrocortisone IM (or IV) on onset of active labour followed by hydrocortisone 200 mg every 24 h via continuous IV infusion or 50 mg every 6 h is recommended | Adjust according to clinical condition or intercurrent conditions<br>For the first 2–4 days, maintain a double oral dose<br>If there are no complications, the preconception dose can be restored thereafter |
| Patients should be advised of possible adrenal crises and treated accordingly with stress dose covering GC dose adjustment in case of stressful situations (double up the dose for the duration; give parenteral GC in case of vomiting or emergency situations) |  |  |   |  |  |  |
| Thyroid axis   | Insufficient data regarding effects of central hypothyroidism on fertility<br>Thyroid hormones seem to have an important role, so thyroid function must be taken into account when conceiving is difficult   | Patients treated for primary thyroid failure need a 20–50% increase in hormone replacement doses once pregnancy is established<br>Secondary hypothyroidism might not require an increased dose<br>Keep free T <sub>4</sub> and total T <sub>4</sub> in upper half of normal range<br>Monitor every 4–6 weeks | Keep dose stable  | Keep dose stable   | Keep dose stable   | Return to preconception dose   |
| GH axis  | GH treatment might improve fertility   | If GH replacement is not contraindicated, some studies suggest continuing the preconception GH dose<br>GH not approved for pregnancy by FDA and EMA  | Do not start GH treatment<br>If previous GH treatment is continued, GH dose should be reduced by 30–50% | No need for GH<br>Previous GH treatment should be stopped  | No need for GH   | Return to preconception dose   |
| Gonadal axis   | This axis is physiologically suppressed from the very beginning of pregnancy; no need for replacement therapy  |  |   |  |  |  |
| Desmopressin   | No need to increase dose   | Dose increase as needed in relation to clinical setting<br>Pregnancy may unmask mild forms of diabetes insipidus   | –   | –  | Dose adjusted in line with fluid requirement and sodium levels   | Return to preconception dose   |

GC, glucocorticoid; GH, growth hormone; HPA, hypothalamic-pituitary-adrenal; HSD, hydroxysteroid dehydrogenase; IM, intramuscularly; IV, intravenous(ly); T<sub>4</sub>, thyroxine. <sup>1</sup> Prednisone and cortisone both require activation by maternal 11 $\beta$ -HSD1 (to form active prednisolone and cortisol respectively); women on other GCs should be switched to hydrocortisone.

both female and male fertility [112–114]. Thyroid function must therefore be taken into account when attempting to restore fertility. Finally, hypothalamic obesity, which affects 30–77% of patients after craniopharyngioma treatment, could potentially interfere with normal fertility [115].

### Managing Pregnancy

The efficacy of the aforementioned treatment protocols and the rapid development and successful application of ART have led to an increase in the number of women achieving fertility and pregnancy despite underlying hypopituitarism [116]. Research over the last decade has filled the gaps in our understanding of the mechanism governing hormonal changes during pregnancy, the role of the placenta as a true endocrine gland and the interaction between the maternal and fetal endocrine systems [117]. Hormone replacement in endocrinology aims specifically to restore, as far as possible, the physiological hormone secretion pattern [61] and patient well-being.

Generally speaking, there are no randomized controlled trials on pituitary hormone replacement during pregnancy, and decisions are based mainly on expert opinions and observational studies, which usually try to mimic the physiology of normal pregnancy. Table 4 presents suggestions for the management of hypopituitarism in pregnancy.

Glucocorticoid replacement during pregnancy is essential when hypothalamic-pituitary-adrenal function is impaired [118]. Steroid replacement in this context should take into account the potentially greater requirement secondary to the pregnancy-induced changes to the hypothalamic-pituitary-adrenal axis (increased CBG, increased placental corticotropin-releasing hormone secretion [119] and 2- to 3-fold increases in total cortisol concentrations, peaking in the 2nd and 3rd trimesters) [120], aiming to avoid undesirable effects on the fetus. Women appropriately treated with replacement therapy can expect to have uneventful pregnancies of a normal duration, with no fetal compromise. However, unrecognized or inappropriately treated adrenal insufficiency in pregnant women can lead to harmful effects on both the mother

(increased morbidity and mortality) and the fetus (reduced birth weight, neurodevelopmental problems and cardiometabolic diseases) [90].

In principle, various glucocorticoid formulations (hydrocortisone, cortisone acetate, prednisone and prednisolone) can be used during pregnancy. However, prednisone and cortisone acetate both need to be activated by maternal 11 $\beta$ -hydroxysteroid dehydrogenase (11 $\beta$ -HSD) type 1. For this reason, and because of its deactivation by placental 11 $\beta$ -HSD type 2, the only recommended formulation is hydrocortisone, as it cannot cross the placenta into the fetal circulation and does not cause any undesirable effects in the fetus.

Current knowledge about steroid replacement during pregnancy is mainly derived from data obtained from Addison's disease, but when considering a replacement for a secondary form of adrenal insufficiency, it should be borne in mind that lower doses are normally needed, without any mineralocorticoid replacement. Hydrocortisone is usually prescribed 3 times daily to follow the circadian rhythm, with a suggested dose of 12–15 mg/m<sup>2</sup>/day, tapered according to clinical judgment, by closely monitoring signs and symptoms of over- and underreplacement [121]. Although there is no universal consensus, some experts suggest increasing the total dose by 20–40% in the last trimester [122], in line with the physiological increase in free cortisol during this trimester. Emergency steroid cover during the active phase of labour, delivery and caesarean section is crucial, as these are all stressful situations requiring intravenous administration of hydrocortisone (50 mg in the second stage of labour/delivery, and 50–100 mg preoperatively and every 8 h postoperatively for caesarean section). After delivery, double the pre-conception dose should be given for the first 2–4 days, and, provided that no complications are affecting the mother, a pre-pregnancy dose can be safely restored thereafter [123]. It should be noted that dexamethasone is not deactivated by placental 11 $\beta$ -HSD type 2, and so is contraindicated during pregnancy.

Thyroid hormones are essential for normal fetal cognitive development. The increased demand for thyroid hormones during pregnancy is normally guaranteed by binding of the placental hCG to the TSH receptor, leading to a physiological "hyperthyroidism," especially during the 1st trimester [124]. The current guidelines thus suggest that patients treated for primary thyroid failure need a 20–50% increase in their HRT doses once pregnancy is established [125]. However, this may not fully apply to secondary hypothyroidism. If thyroid function is intact, hCG stimulation could guarantee normal thyroid hor-

monone production, meaning that replacement therapy might not be needed. In these cases, free and total thyroxine should be carefully monitored, aiming to maintain their levels in the upper half of the normal range [126]. After delivery, thyroid replacement doses should be reduced to pre-pregnancy doses.

In contrast, GH replacement therapy during gestation is controversial. Current evidence on the physiology of GH secretion during pregnancy shows that GH is still secreted until mid-gestation; therefore, continuation of GH therapy, at least in the 1st trimester, could be theoretically advocated. For this reason, some experts continue GH therapy at the same dose in the 1st trimester and at half the dose in the 2nd trimester, stopping it altogether in the last trimester [127]. However, no randomized controlled trials have been conducted on the effects of GH therapy during pregnancy, and current Endocrine Society guidelines recommend stopping GH during conception and pregnancy [92].

Physiologically, the HPG axis is suppressed from the very beginning of pregnancy, so no treatment is recommended in relation to hormones.

Desmopressin therapy can be safely continued or started during pregnancy [61]. Due to the naturally increased total body water, expanded plasma volume and increased maternal vasopressin in pregnancy, dose adjustment may be necessary for some but not all patients with previous DI. Clinicians should monitor the signs and symptoms of DI both clinically (polyuria-polydipsia) and biochemically (plasma osmolality and serum sodium) [128], as the water deprivation test is not recommended [129].

## Conclusions

In recent decades, progress in parasellar tumour diagnosis and treatment has led to a great improvement in survival rates. Strategies for identifying patients with delayed puberty and instituting timely pubertal induction in adolescence can significantly improve long-term sexual and reproductive function. A correct identification of delayed puberty and personalization of puberty induction therapy with androgens and/or gonadotropins are crucial with these patients. Long-term physiological testosterone replacement is necessary for men with permanent HH, to substitute HPG function and to reduce comorbidities associated with HH.

In girls with a diagnosis of HH secondary to parasellar lesion treatment, oestrogen replacement therapy should

be promptly started with the proposed protocols; if hypogonadism arises after puberty, HRT is necessary until or beyond the age of natural menopause to protect female patients from metabolic, cardiovascular and bone diseases associated with HH.

Post-treatment preservation of fertility and quality of life is therefore crucial. Whenever possible, fertility aspects should be discussed before starting therapies leading to hypogonadism and infertility. Unfortunately, about 40% of cancer survivors report that no fertility counselling was offered after their diagnosis. Fertility preservation strategies are available, and several studies are evaluating further new alternatives. A multidisciplinary approach involving oncologists, radiotherapists, endocrinologists, gynaecologists and fertility specialists is essential to improve the awareness and availability of these options. As ART regimens continuously change and fertility options improve, future studies on patients with hypopituitarism are needed to find a patient-tailored strategy for restoring hormonal function, when possible, and preserving the patient's reproductive potential.

## Acknowledgement

We wish to thank Marie-Hélène Hayles for her assistance with medical writing during the preparation of the manuscript.

## References

- 1 Freda PU, Post KD. Differential diagnosis of sellar masses. *Endocrinol Metab Clin North Am*. 1999 Mar;28(1):81–117.
- 2 Kaltsas GA, Evanson J, Chrisoulidou A, Grossman AB. The diagnosis and management of parasellar tumours of the pituitary. *Endocr Relat Cancer*. 2008 Dec;15(4):885–903.
- 3 Rennert J, Doerfler A. Imaging of sellar and parasellar lesions. *Clin Neurol Neurosurg*. 2007 Feb;109(2):111–24.
- 4 Vitale G, Tortora F, Baldelli R, Cocchiara F, Paragiola RM, Sbardella E, et al.; A.B.C. Group. Pituitary magnetic resonance imaging in Cushing's disease. *Endocrine*. 2017 Mar; 55(3):691–6.
- 5 Sbardella E, Joseph RN, Jafar-Mohammadi B, Isidori AM, Cudlip S, Grossman AB. Pituitary stalk thickening: the role of an innovative MRI imaging analysis which may assist in determining clinical management. *Eur J Endocrinol*. 2016 Oct;175(4):255–63.
- 6 Tosaka M, Higuchi T, Horiguchi K, Osawa T, Arisaka Y, Fujita H, et al. Preoperative Evaluation of Sellar and Parasellar Macroadenomas by [18F]Fluorodeoxyglucose Positron Emission Tomography. *World Neurosurg*. 2017 Jul; 103:591–9.
- 7 Fani M, Nicolas GP, Wild D. Somatostatin Receptor Antagonists for Imaging and Therapy. *J Nucl Med*. 2017 Sep;58 Suppl 2:61S–66S.
- 8 Giannetta E, Gianfrilli D, Barbagallo F, Isidori AM, Lenzi A. Subclinical male hypogonadism. *Best Pract Res Clin Endocrinol Metab*. 2012 Aug;26(4):539–50.
- 9 Juul A, Hagen CP, Aksglaede L, Sørensen K, Mouritsen A, Frederiksen H, et al. Endocrine evaluation of reproductive function in girls during infancy, childhood and adolescence. *Endocr Dev*. 2012;22:24–39.
- 10 Chammas NK, Chambers SM, Harris PE. The GnRH test in the assessment of patients with pituitary and paraspituitary lesions: results of a 5-year retrospective study. *Pituitary*. 2008; 11(3):271–8.
- 11 Harrington J, Palmert MR. Clinical review: Distinguishing constitutional delay of growth and puberty from isolated hypogonadotropic hypogonadism: critical appraisal of available diagnostic tests. *J Clin Endocrinol Metab*. 2012 Sep;97(9):3056–67.
- 12 Bhakta N, Liu Q, Ness KK, Baassiri M, Eissa H, Yeo F, et al. The cumulative burden of surviving childhood cancer: an initial report from the St Jude Lifetime Cohort Study (SJLIFE). *Lancet*. 2017 Dec;390(10112):2569–82.
- 13 Crowne E, Gleeson H, Benghiat H, Sanghera P, Toogood A. Effect of cancer treatment on hypothalamic-pituitary function. *Lancet Diabetes Endocrinol*. 2015 Jul;3(7):568–76.
- 14 Chemaitilly W, Cohen LE. Diagnosis of endocrine disease: endocrine late-effects of childhood cancer and its treatments. *Eur J Endocrinol*. 2017 Apr;176(4):R183–203.
- 15 Chemaitilly W, Cohen LE, Mostoufi-Moab S, Patterson BC, Simmons JH, Meacham LR, et al. Endocrine Late Effects in Childhood Cancer Survivors. *J Clin Oncol*. 2018 Jul;36(21): 2153–9.
- 16 Gleeson HK, Stoeter R, Ogilvy-Stuart AL, Gattamaneni HR, Brennan BM, Shalet SM. Improvements in final height over 25 years in growth hormone (GH)-deficient childhood survivors of brain tumors receiving GH replacement. *J Clin Endocrinol Metab*. 2003 Aug;88(8):3682–9.

## Conflict of Interest Statement

A.M.I. received consultation fees, unconditional grants and conference hospitality from IBSA, Takeda and Ipsen. D.G. received an unconditional contribution from MSD Italia. E.S., M.M., R.P., A.C. and E.G. have nothing to disclose.

## Funding Sources

No funding was used to conduct this study or produce this manuscript.

## Author Contributions

E.S.: substantial contributions to conception of the manuscript, acquisition of data, analysis and interpretation of data, drafting the article, revising it critically for important intellectual content, and final approval of the version to be submitted. M.M. and R.P.: substantial contributions to conception of the manuscript, acquisition of data, analysis and interpretation of data, and drafting the article. A.C. and E.G.: substantial contributions to acquisition of data, analysis of data, and revising the manuscript critically for important intellectual content. D.G.: substantial contributions to conception of the manuscript, drafting the article, revising it critically for important intellectual content, and final approval of the version to be submitted. A.M.I.: substantial contributions to conception and design of the manuscript, drafting the article and revising it critically for important intellectual content, and final approval of the version to be submitted.

- 17 Chemaitilly W, Merchant TE, Li Z, Barnes N, Armstrong GT, Ness KK, et al. Central precocious puberty following the diagnosis and treatment of paediatric cancer and central nervous system tumours: presentation and long-term outcomes. *Clin Endocrinol (Oxf)*. 2016 Mar;84(3):361–71.
- 18 Storr HL, Alexandraki KI, Martin L, Isidori AM, Kaltsas GA, Monson JP, et al. Comparisons in the epidemiology, diagnostic features and cure rate by transsphenoidal surgery between paediatric and adult-onset Cushing's disease. *Eur J Endocrinol*. 2011 May;164(5):667–74.
- 19 Sbardella E, Isidori AM, Woods CP, Argese N, Tomlinson JW, Shine B, et al. Baseline morning cortisol level as a predictor of pituitary-adrenal reserve: a comparison across three assays. *Clin Endocrinol (Oxf)*. 2017 Feb;86(2):177–84.
- 20 Pofi R, Feliciano C, Sbardella E, Argese N, Woods CP, Grossman AB, et al. The Short Synacthen (Corticotropin) Test Can Be Used to Predict Recovery of Hypothalamo-Pituitary-Adrenal Axis Function. *J Clin Endocrinol Metab*. 2018 Aug;103(8):3050–9.
- 21 Kaltsas GA, Kolomodi D, Randeva H, Grossman A. Nonneuroendocrine Neoplasms of the Pituitary Region. *J Clin Endocrinol Metab*. 2019 Aug;104(8):3108–23.
- 22 Isidori AM, Arnaldi G, Boscaro M, Falorni A, Giordano C, Giordano R, et al. Towards the tailoring of glucocorticoid replacement in adrenal insufficiency: the Italian Society of Endocrinology Expert Opinion. *J Endocrinol Invest*. 2020 May;43(5):683–96.
- 23 Isidori AM, Venneri MA, Graziadio C, Simeoli C, Fiore D, Hasenmajer V, et al. Effect of once-daily, modified-release hydrocortisone versus standard glucocorticoid therapy on metabolism and innate immunity in patients with adrenal insufficiency (DREAM): a single-blind, randomised controlled trial. *Lancet Diabetes Endocrinol*. 2018 Mar;6(3):173–85.
- 24 Venneri MA, Hasenmajer V, Fiore D, Sbardella E, Pofi R, Graziadio C, et al. Circadian Rhythm of Glucocorticoid Administration Entrain Clock Genes in Immune Cells: A DREAM Trial Ancillary Study. *J Clin Endocrinol Metab*. 2018 Aug;103(8):2998–3009.
- 25 Alexandraki KI, Grossman A. Management of Hypopituitarism. *J Clin Med*. 2019 Dec;8(12):E2153.
- 26 van Santen HM, van den Heuvel-Eibrink MM, van de Wetering MD, Wallace WH. Hypogonadism in Children with a Previous History of Cancer: Endocrine Management and Follow-Up. *Horm Res Paediatr*. 2019;91(Suppl 2):93–103.
- 27 Clement SC, Schouten-van Meeteren AY, Boot AM, Claahsen-van der Grinten HL, Granzan B, Sen Han K, et al. Prevalence and Risk Factors of Early Endocrine Disorders in Childhood Brain Tumor Survivors: A Nationwide, Multicenter Study. *J Clin Oncol*. 2016 Dec;34(36):4362–70.
- 28 Armstrong GT, Liu Q, Yasui Y, Huang S, Ness KK, Leisenring W, et al. Long-term outcomes among adult survivors of childhood central nervous system malignancies in the Childhood Cancer Survivor Study. *J Natl Cancer Inst*. 2009 Jul;101(13):946–58.
- 29 van Iersel L, Li Z, Srivastava DK, Brinkman TM, Bjornard KL, Wilson CL, et al. Hypothalamic-Pituitary Disorders in Childhood Cancer Survivors: Prevalence, Risk Factors and Long-Term Health Outcomes. *J Clin Endocrinol Metab*. 2019 Dec;104(12):6101–15.
- 30 Lawrence YR, Li XA, el Naqa I, Hahn CA, Marks LB, Merchant TE, et al. Radiation dose-volume effects in the brain. *Int J Radiat Oncol Biol Phys*. 2010 Mar;76(3 Suppl):S20–7.
- 31 Clayton PE, Shalet SM. Dose dependency of time of onset of radiation-induced growth hormone deficiency. *J Pediatr*. 1991 Feb;118(2):226–8.
- 32 Spoudeas HA, Hindmarsh PC, Matthews DR, Brook CG. Evolution of growth hormone neurosecretory disturbance after cranial irradiation for childhood brain tumours: a prospective study. *J Endocrinol*. 1996 Aug;150(2):329–42.
- 33 Duffner PK, Cohen ME, Voorhess ML, MacGillivray MH, Brecher ML, Panahon A, et al. Long-term effects of cranial irradiation on endocrine function in children with brain tumors. A prospective study. *Cancer*. 1985 Nov;56(9):2189–93.
- 34 Lam KS, Tse VK, Wang C, Yeung RT, Ho JH. Effects of cranial irradiation on hypothalamic-pituitary function – a 5-year longitudinal study in patients with nasopharyngeal carcinoma. *Q J Med*. 1991 Feb;78(286):165–76.
- 35 Scaringi C, Agolli L, Minniti G. Technical Advances in Radiation Therapy for Brain Tumors. *Anticancer Res*. 2018 Nov;38(11):6041–5.
- 36 Minniti G, Flickinger J. The risk/benefit ratio of radiotherapy in pituitary tumors. *Best Pract Res Clin Endocrinol Metab*. 2019 Apr;33(2):101269.
- 37 Veldhuis JD. The hypothalamic pulse generator: the reproductive core. *Clin Obstet Gynecol*. 1990 Sep;33(3):538–50.
- 38 Darzy KH, Shalet SM. Hypopituitarism following radiotherapy. *Pituitary*. 2009;12(1):40–50.
- 39 Marci R, Mallozzi M, Di Benedetto L, Schimberni M, Mossa S, Soave I, et al. Radiations and female fertility. *Reprod Biol Endocrinol*. 2018 Dec;16(1):112.
- 40 Meirou D, Biederman H, Anderson RA, Wallace WH. Toxicity of chemotherapy and radiation on female reproduction. *Clin Obstet Gynecol*. 2010 Dec;53(4):727–39.
- 41 Rose SR, Horne VE, Howell J, Lawson SA, Rutter MM, Trotman GE, et al. Late endocrine effects of childhood cancer. *Nat Rev Endocrinol*. 2016 Jun;12(6):319–36.
- 42 Sbardella E, Tenuta M, Sirgiovanni G, Gianfrilli D, Pozza C, Venneri MA, et al. Thyroid disorders in programmed death 1 inhibitor-treated patients: is previous therapy with tyrosine kinase inhibitors a predisposing factor? *Clin Endocrinol (Oxf)*. 2020 Mar;92(3):258–65.
- 43 Robert C, Thomas L, Bondarenko I, O'Day S, Weber J, Garbe C, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. *N Engl J Med*. 2011 Jun;364(26):2517–26.
- 44 Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. *N Engl J Med*. 2010 Aug;363(8):711–23.
- 45 Min L, Vaidya A, Becker C. Association of ipilimumab therapy for advanced melanoma with secondary adrenal insufficiency: a case series. *Endocr Pract*. 2012 May-Jun;18(3):351–5.
- 46 Dillard T, Yedinak CG, Alumkal J, Fleseriu M. Anti-CTLA-4 antibody therapy associated autoimmune hypophysitis: serious immune related adverse events across a spectrum of cancer subtypes. *Pituitary*. 2010;13(1):29–38.
- 47 Barnard ZR, Walcott BP, Kahle KT, Nahed BV, Coumans JV. Hyponatremia associated with Ipilimumab-induced hypophysitis. *Med Oncol*. 2012 Mar;29(1):374–7.
- 48 Zatelli MC, Ambrosio MR, Bondanelli M, Degli Uberti E. Pituitary side effects of old and new drugs. *J Endocrinol Invest*. 2014 Oct;37(10):917–23.
- 49 Corsello SM, Barnabei A, Marchetti P, De Vecchis L, Salvatori R, Torino F. Endocrine side effects induced by immune checkpoint inhibitors. *J Clin Endocrinol Metab*. 2013 Apr;98(4):1361–75.
- 50 Minnetti M, Caiulo S, Ferrigno R, Baldini-Ferroli B, Bottaro G, Gianfrilli D, et al. Abnormal linear growth in paediatric adrenal diseases: pathogenesis, prevalence and management. *Clin Endocrinol (Oxf)*. 2020 Feb;92(2):98–108.
- 51 Bin-Abbas B, Conte FA, Grumbach MM, Kaplan SL. Congenital hypogonadotropic hypogonadism and micropenis: effect of testosterone treatment on adult penile size why sex reversal is not indicated. *J Pediatr*. 1999 May;134(5):579–83.
- 52 Dunkel L, Quinton R. Transition in endocrinology: induction of puberty. *Eur J Endocrinol*. 2014 Jun;170(6):R229–39.
- 53 Defeudis G, Gianfrilli D, Di Emidio C, Pofi R, Tuccinardi D, Palermo A, et al. Erectile dysfunction and its management in patients with diabetes mellitus. *Rev Endocr Metab Disord*. 2015 Oct;16(3):213–31.
- 54 Richman RA, Kirsch LR. Testosterone treatment in adolescent boys with constitutional delay in growth and development. *N Engl J Med*. 1988 Dec;319(24):1563–7.



- 55 Zacharin M, Sabin MA, Nair VV, Dabadghao P. Addition of recombinant follicle-stimulating hormone to human chorionic gonadotropin treatment in adolescents and young adults with hypogonadotropic hypogonadism promotes normal testicular growth and may promote early spermatogenesis. *Fertil Steril*. 2012 Oct;98(4):836–42.
- 56 Kim SO, Ryu KH, Hwang IS, Jung SI, Oh KJ, Park K. Penile growth in response to human chorionic gonadotropin (HCG) treatment in patients with idiopathic hypogonadotrophic hypogonadism. *Chonnam Med J*. 2011 Apr;47(1):39–42.
- 57 Rohayem J, Hauffa BP, Zacharin M, Kliesch S, Zitzmann M; “German Adolescent Hypogonadotropic Hypogonadism Study Group”. Testicular growth and spermatogenesis: new goals for pubertal hormone replacement in boys with hypogonadotropic hypogonadism? A multicentre prospective study of hCG/rFSH treatment outcomes during adolescence. *Clin Endocrinol (Oxf)*. 2017 Jan;86(1):75–87.
- 58 Corona G, Goulis DG, Huhtaniemi I, Zitzmann M, Toppari J, Forti G, et al. European Academy of Andrology (EAA) guidelines\* on investigation, treatment and monitoring of functional hypogonadism in males. *Andrology*. 2020 Feb;andr.12770.
- 59 Isidori AM, Balercia G, Calogero AE, Corona G, Ferlin A, Francavilla S, et al. Outcomes of androgen replacement therapy in adult male hypogonadism: recommendations from the Italian society of endocrinology. *J Endocrinol Invest*. 2015 Jan;38(1):103–12.
- 60 Isidori AM, Lenzi A. Risk factors for androgen decline in older males: lifestyle, chronic diseases and drugs. *J Endocrinol Invest*. 2005;28(3 Suppl):14–22.
- 61 Fleseriu M, Hashim IA, Karavitaki N, Melmed S, Murad MH, Salvatori R, et al. Hormonal Replacement in Hypopituitarism in Adults: An Endocrine Society Clinical Practice Guideline. *J Clin Endocrinol Metab*. 2016 Nov;101(11):3888–921.
- 62 Corona G, Rastrelli G, Reisman Y, Sforza A, Maggi M. The safety of available treatments of male hypogonadism in organic and functional hypogonadism. *Expert Opin Drug Saf*. 2018 Mar;17(3):277–92.
- 63 Isidori AM, Giannetta E, Lenzi A. Male hypogonadism. *Pituitary*. 2008;11(2):171–80.
- 64 Büchter D, Behre HM, Kliesch S, Nieschlag E. Pulsatile GnRH or human chorionic gonadotropin/human menopausal gonadotropin as effective treatment for men with hypogonadotropic hypogonadism: a review of 42 cases. *Eur J Endocrinol*. 1998 Sep;139(3):298–303.
- 65 Ramasamy R, Armstrong JM, Lipshultz LI. Preserving fertility in the hypogonadal patient: an update. *Asian J Androl*. 2015 Mar-Apr;17(2):197–200.
- 66 Isidori AM, Pozza C, Gianfrilli D, Isidori A. Medical treatment to improve sperm quality. *Reprod Biomed Online*. 2006 Jun;12(6):704–14.
- 67 Saal W, Glowania HJ, Hengst W, Happ J. Pharmacodynamics and pharmacokinetics after subcutaneous and intramuscular injection of human chorionic gonadotropin. *Fertil Steril*. 1991 Aug;56(2):225–9.
- 68 Warne DW, Decosterd G, Okada H, Yano Y, Koide N, Howles CM. A combined analysis of data to identify predictive factors for spermatogenesis in men with hypogonadotropic hypogonadism treated with recombinant human follicle-stimulating hormone and human chorionic gonadotropin. *Fertil Steril*. 2009 Aug;92(2):594–604.
- 69 Rastrelli G, Corona G, Mannucci E, Maggi M. Factors affecting spermatogenesis upon gonadotropin-replacement therapy: a meta-analytic study. *Andrology*. 2014 Nov;2(6):794–808.
- 70 Prior M, Stewart J, McEleny K, Dwyer AA, Quinton R. Fertility induction in hypogonadotropic hypogonadal men. *Clin Endocrinol (Oxf)*. 2018 Dec;89(6):712–8.
- 71 Jungwirth A, Giwercman A, Tournaye H, Diemer T, Kopa Z, Dohle G, et al.; European Association of Urology Working Group on Male Infertility. European Association of Urology guidelines on Male Infertility: the 2012 update. *Eur Urol*. 2012 Aug;62(2):324–32.
- 72 Han TS, Bouloux PM. What is the optimal therapy for young males with hypogonadotropic hypogonadism? *Clin Endocrinol (Oxf)*. 2010 Jun;72(6):731–7.
- 73 Anawalt BD. Approach to male infertility and induction of spermatogenesis. *J Clin Endocrinol Metab*. 2013 Sep;98(9):3532–42.
- 74 Zorn B, Pfeifer M, Virant-Klun I, Meden-Vrtovec H. Intracytoplasmic sperm injection as a complement to gonadotrophin treatment in infertile men with hypogonadotrophic hypogonadism. *Int J Androl*. 2005 Aug;28(4):202–7.
- 75 Nilsson S, Hellberg D. Recovery of spermatozoa after rFSH/hCG treatment, and subsequent ICSI/IVF, in a male with testicular atrophy due to severe congenital hypogonadotrophic hypogonadism. *Arch Androl*. 2006 Mar-Apr;52(2):135–8.
- 76 Frapsauce C, Ravel C, Legendre M, Sibony M, Mandelbaum J, Donadille B, et al. Birth after TESE-ICSI in a man with hypogonadotropic hypogonadism and congenital adrenal hypoplasia linked to a DAX-1 (NR0B1) mutation. *Hum Reprod*. 2011 Mar;26(3):724–8.
- 77 Ogilvy-Stuart AL, Clayton PE, Shalet SM. Cranial irradiation and early puberty. *J Clin Endocrinol Metab*. 1994 Jun;78(6):1282–6.
- 78 Wei C, Crowne E. The impact of childhood cancer and its treatment on puberty and subsequent hypothalamic pituitary and gonadal function, in both boys and girls. *Best Pract Res Clin Endocrinol Metab*. 2019 Jun;33(3):101291.
- 79 Sbardella E, Pozza C, Isidori AM, Grossman AB. Endocrinology and adolescence: dealing with transition in young patients with pituitary disorders. *Eur J Endocrinol*. 2019 Oct;181(4):R155–71.
- 80 Rosén T, Wilhelmsen L, Landin-Wilhelmsen K, Lappas G, Bengtsson BA. Increased fracture frequency in adult patients with hypopituitarism and GH deficiency. *Eur J Endocrinol*. 1997 Sep;137(3):240–5.
- 81 Goodman MP. Are all estrogens created equal? A review of oral vs transdermal therapy. *J Womens Health (Larchmt)*. 2012 Feb;21(2):161–9.
- 82 Mohammed K, Abu Dabrh AM, Benkhadra K, Al Nofal A, Carranza Leon BG, Prokop LJ, et al. Oral vs Transdermal Estrogen Therapy and Vascular Events: A Systematic Review and Meta-Analysis. *J Clin Endocrinol Metab*. 2015 Nov;100(11):4012–20.
- 83 Sitruk-Ware R, Nath A. Characteristics and metabolic effects of estrogen and progestins contained in oral contraceptive pills. *Best Pract Res Clin Endocrinol Metab*. 2013 Feb;27(1):13–24.
- 84 Webber L, Davies M, Anderson R, Bartlett J, Braat D, Cartwright B, et al.; European Society for Human Reproduction and Embryology (ESHRE) Guideline Group on POI. ESHRE Guideline: management of women with premature ovarian insufficiency. *Hum Reprod*. 2016 May;31(5):926–37.
- 85 Davis SR, Baber R, Panay N, Bitzer J, Perez SC, Islam RM, et al. Global Consensus Position Statement on the Use of Testosterone Therapy for Women. *J Clin Endocrinol Metab*. 2019 Oct;104(10):4660–6.
- 86 de Boer JA, Schoemaker J, van der Veen EA. Impaired reproductive function in women treated for growth hormone deficiency during childhood. *Clin Endocrinol (Oxf)*. 1997 Jun;46(6):681–9.
- 87 Hall R, Manski-Nankervis J, Goni N, Davies MC, Conway GS. Fertility outcomes in women with hypopituitarism. *Clin Endocrinol (Oxf)*. 2006 Jul;65(1):71–4.
- 88 Correa FA, Bianchi PH, Franca MM, Otto AP, Rodrigues RJ, Ejzenberg D, et al. Successful Pregnancies after Adequate Hormonal Replacement in Patients with Combined Pituitary Hormone Deficiencies. *J Endocr Soc*. 2017 Sep;1(10):1322–30.
- 89 White DM, Hardy K, Lovelock S, Franks S. Low-dose gonadotropin induction of ovulation in anovulatory women: still needed in the age of IVF. *Reproduction*. 2018 Jul;156(1):F1–10.
- 90 Vila G, Fleseriu M. Fertility and Pregnancy in Women with Hypopituitarism: A Systematic Literature Review. *J Clin Endocrinol Metab*. 2020 Mar;105(3):dgz112.
- 91 Tsilchorozidou T, Conway GS. Uterus size and ovarian morphology in women with isolated growth hormone deficiency, hypogonadotrophic hypogonadism and hypopituitarism. *Clin Endocrinol (Oxf)*. 2004 Nov;61(5):567–72.
- 92 Vila G, Akerblad AC, Mattsson AF, Riedl M, Webb SM, Hana V, et al. Pregnancy outcomes in women with growth hormone deficiency. *Fertil Steril*. 2015 Nov;104(5):1210–7.e1.



- 93 Shinar S, Many A, Maslovitz S. Questioning the role of pituitary oxytocin in parturition: spontaneous onset of labor in women with panhypopituitarism – a case series. *Eur J Obstet Gynecol Reprod Biol*. 2016 Feb;197:83–5.
- 94 Tranoulis A, Laios A, Pampanos A, Yannoukakos D, Loutradis D, Michala L. Efficacy and safety of pulsatile gonadotropin-releasing hormone therapy among patients with idiopathic and functional hypothalamic amenorrhea: a systematic review of the literature and a meta-analysis. *Fertil Steril*. 2018 Apr;109(4):708–19.e8.
- 95 Martin KA, Hall JE, Adams JM, Crowley WF Jr. Comparison of exogenous gonadotropins and pulsatile gonadotropin-releasing hormone for induction of ovulation in hypogonadotropic amenorrhea. *J Clin Endocrinol Metab*. 1993 Jul;77(1):125–9.
- 96 Pandurangi M, Tamizharasi M, Reddy NS. Pregnancy outcome of assisted reproductive technology cycle in patients with hypogonadotropic hypogonadism. *J Hum Reprod Sci*. 2015 Jul-Sep;8(3):146–50.
- 97 Kumbak B, Kahraman S. Women with hypogonadotropic hypogonadism: cycle characteristics and results of assisted reproductive techniques. *Acta Obstet Gynecol Scand*. 2006;85(12):1453–7.
- 98 Ghaffari F, Arabipoor A, Lankarani NB, Eteminan Z, Tehraninejad ES. Assisted reproductive technique outcomes in hypogonadotropic hypogonadism women. *Ann Saudi Med*. 2013 May-Jun;33(3):235–40.
- 99 Jiang S, Kuang Y. The effects of low-dose human chorionic gonadotropin combined with human menopausal gonadotropin protocol on women with hypogonadotropic hypogonadism undergoing ovarian stimulation for in vitro fertilization. *Clin Endocrinol (Oxf)*. 2018 Jan;88(1):77–87.
- 100 Du X, Yuan Q, Yao Y, Li Z, Zhang H. Hypopituitarism and successful pregnancy. *Int J Clin Exp Med*. 2014 Dec;7(12):4660–5.
- 101 Cecchino GN, Canillas GM, Cruz M, García-Velasco JA. Impact of hypogonadotropic hypogonadism on ovarian reserve and response. *J Assist Reprod Genet*. 2019 Nov;36(11):2379–84.
- 102 Huseyin K, Berk B, Tolga K, Eser O, Ali G, Murat A. Management of ovulation induction and intrauterine insemination in infertile patients with hypogonadotropic hypogonadism. *J Gynecol Obstet Hum Reprod*. 2019 Dec;48(10):833–8.
- 103 Hull KL, Harvey S. Growth hormone and reproduction: a review of endocrine and autocrine/paracrine interactions. *Int J Endocrinol*. 2014;2014:234014.
- 104 Magon N, Singh S, Saxena A, Sahay R. Growth hormone in male infertility. *Indian J Endocrinol Metab*. 2011 Sep;15(7 Suppl 3):S248–9.
- 105 Hubina E, Mersebach H, Rasmussen AK, Juul A, Sneppen SB, Góth MI, et al. Effect of growth hormone replacement therapy on pituitary hormone secretion and hormone replacement therapies in GHD adults. *Horm Res*. 2004;61(5):211–7.
- 106 Breier BH, Vickers MH, Gravance CG, Casey PJ. Therapy with growth hormone: major prospects for the treatment of male subfertility? *Endocr J*. 1998 Apr;45 Suppl:S53–60.
- 107 Lee KO, Ng SC, Lee PS, Bongso AT, Taylor EA, Lin TK, et al. Effect of growth hormone therapy in men with severe idiopathic oligozoospermia. *Eur J Endocrinol*. 1995 Feb;132(2):159–62.
- 108 Bachelot A, Monget P, Imbert-Bolloré P, Coshigano K, Kopchick JJ, Kelly PA, et al. Growth hormone is required for ovarian follicular growth. *Endocrinology*. 2002 Oct;143(10):4104–12.
- 109 Albu D, Albu A. Is growth hormone administration essential for in vitro fertilization treatment of female patients with growth hormone deficiency? *Syst Biol Reprod Med*. 2019 Feb;65(1):71–4.
- 110 Giampietro A, Milardi D, Bianchi A, Fusco A, Cimino V, Valle D, et al. The effect of treatment with growth hormone on fertility outcome in eugonadal women with growth hormone deficiency: report of four cases and review of the literature. *Fertil Steril*. 2009 Mar;91(3):930.e7–11.
- 111 Hart RJ, Rombauts L, Norman RJ. Growth hormone in IVF cycles: any hope? *Curr Opin Obstet Gynecol*. 2017 Jun;29(3):119–25.
- 112 Patel DP, Chandrapal JC, Hotaling JM. Hormone-Based Treatments in Subfertile Males. *Curr Urol Rep*. 2016 Aug;17(8):56.
- 113 Nikoobakht MR, Aloosh M, Nikoobakht N, Mehryar AR, Biniaz F, Karjalainen MA. The role of hypothyroidism in male infertility and erectile dysfunction. *Urol J*. 2012;9(1):405–9.
- 114 Madhukar D, Rajender S. Hormonal treatment of male infertility: promises and pitfalls. *J Androl*. 2009 Mar-Apr;30(2):95–112.
- 115 Lustig RH. Hypothalamic obesity after craniopharyngioma: mechanisms, diagnosis, and treatment. *Front Endocrinol (Lausanne)*. 2011 Nov;2:60.
- 116 Niederberger C, Pellicer A, Cohen J, Gardner DK, Palermo GD, O'Neill CL, et al. Forty years of IVF. *Fertil Steril*. 2018 Jul;110(2):185–324.e5.
- 117 Murphy VE, Smith R, Giles WB, Clifton VL. Endocrine regulation of human fetal growth: the role of the mother, placenta, and fetus. *Endocr Rev*. 2006 Apr;27(2):141–69.
- 118 Sherlock M, Ayuk J, Tomlinson JW, Toogood AA, Aragon-Alonso A, Sheppard MC, et al. Mortality in patients with pituitary disease. *Endocr Rev*. 2010 Jun;31(3):301–42.
- 119 Pofi RT, Tomlinson JW. Glucocorticoid in Pregnancy. *Obstet Med*. 2019;1753495X1984783.
- 120 Jung C, Ho JT, Torpy DJ, Rogers A, Doogue M, Lewis JG, et al. A longitudinal study of plasma and urinary cortisol in pregnancy and postpartum. *J Clin Endocrinol Metab*. 2011 May;96(5):1533–40.
- 121 Langlois F, Lim DS, Fleseriu M. Update on adrenal insufficiency: diagnosis and management in pregnancy. *Curr Opin Endocrinol Diabetes Obes*. 2017 Jun;24(3):184–92.
- 122 Bancos I, Hahner S, Tomlinson J, Arlt W. Diagnosis and management of adrenal insufficiency. *Lancet Diabetes Endocrinol*. 2015 Mar;3(3):216–26.
- 123 Bornstein SR, Allolio B, Arlt W, Barthel A, Don-Wauchope A, Hammer GD, et al. Diagnosis and Treatment of Primary Adrenal Insufficiency: An Endocrine Society Clinical Practice Guideline. *J Clin Endocrinol Metab*. 2016 Feb;101(2):364–89.
- 124 Lockwood CM, Grenache DG, Gronowski AM. Serum human chorionic gonadotropin concentrations greater than 400,000 IU/L are invariably associated with suppressed serum thyrotropin concentrations. *Thyroid*. 2009 Aug;19(8):863–8.
- 125 Alexander EK, Pearce EN, Brent GA, Brown RS, Chen H, Dosiou C, et al. 2017 Guidelines of the American Thyroid Association for the Diagnosis and Management of Thyroid Disease during Pregnancy and the Postpartum. *Thyroid*. 2017 Mar;27(3):315–89.
- 126 Persani L, Brabant G, Dattani M, Bonomi M, Feldt-Rasmussen U, Fliers E, et al. 2018 European Thyroid Association (ETA) Guidelines on the Diagnosis and Management of Central Hypothyroidism. *Eur Thyroid J*. 2018 Oct;7(5):225–37.
- 127 de Zegher F, Vanderschueren-Lodeweyckx M, Spitz B, Faijerson Y, Blomberg F, Beckers A, et al. Perinatal growth hormone (GH) physiology: effect of GH-releasing factor on maternal and fetal secretion of pituitary and placental GH. *J Clin Endocrinol Metab*. 1990 Aug;71(2):520–2.
- 128 Ananthakrishnan S. Diabetes insipidus during pregnancy. *Best Pract Res Clin Endocrinol Metab*. 2016 Mar;30(2):305–15.
- 129 Marques P, Gunawardana K, Grossman A. Transient diabetes insipidus in pregnancy. *Endocrinol Diabetes Metab Case Rep*. 2015;2015:150078.
- 130 Balen AH, Braat DD, West C, Patel A, Jacobs HS. Cumulative conception and live birth rates after the treatment of anovulatory infertility: safety and efficacy of ovulation induction in 200 patients. *Hum Reprod*. 1994 Aug;9(8):1563–70.
- 131 Kaufmann R, Dunn R, Vaughn T, Hughes G, O'Brien F, Hemsey G, et al. Recombinant human luteinizing hormone, lutropin alfa, for the induction of follicular development and pregnancy in profoundly gonadotrophin-deficient women. *Clin Endocrinol (Oxf)*. 2007 Oct;67(4):563–9.
- 132 Carone D, Caropreso C, Vitti A, Chiappetta R. Efficacy of different gonadotropin combinations to support ovulation induction in WHO type I anovulation infertility: clinical evidences of human recombinant FSH/human recombinant LH in a 2:1 ratio and highly purified human menopausal gonadotropin stimulation protocols. *J Endocrinol Invest*. 2012 Dec;35(11):996–1002.